AlzeCure Pharma Management
Management criteria checks 3/4
AlzeCure Pharma's CEO is Martin Jönsson, appointed in Jan 2020, has a tenure of 4.33 years. total yearly compensation is SEK2.41M, comprised of 68.2% salary and 31.8% bonuses, including company stock and options. directly owns 0.66% of the company’s shares, worth SEK773.89K. The average tenure of the management team and the board of directors is 4.3 years and 6.3 years respectively.
Key information
Martin Jönsson
Chief executive officer
kr2.4m
Total compensation
| CEO salary percentage | 68.2% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.7% |
| Management average tenure | 4.3yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth
Dec 02
Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth
Jul 20Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?
Oct 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jan 03Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jul 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Mar 28Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares
Feb 03We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate
Dec 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -kr37m |
| Dec 31 2023 | n/a | n/a | -kr37m |
| Sep 30 2023 | n/a | n/a | -kr38m |
| Jun 30 2023 | n/a | n/a | -kr42m |
| Mar 31 2023 | n/a | n/a | -kr53m |
| Dec 31 2022 | kr2m | kr2m | -kr56m |
| Sep 30 2022 | n/a | n/a | -kr68m |
| Jun 30 2022 | n/a | n/a | -kr73m |
| Mar 31 2022 | n/a | n/a | -kr67m |
| Dec 31 2021 | kr2m | kr2m | -kr78m |
| Sep 30 2021 | n/a | n/a | -kr73m |
| Jun 30 2021 | n/a | n/a | -kr78m |
| Mar 31 2021 | n/a | n/a | -kr81m |
| Dec 31 2020 | kr2m | kr1m | -kr71m |
Compensation vs Market: Martin's total compensation ($USD219.48K) is about average for companies of similar size in the Swedish market ($USD240.79K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
CEO
Martin Jönsson (55 yo)
4.3yrs
Tenure
kr2,414,000
Compensation
Mr. Martin Jönsson is the Chief Executive Officer of AlzeCure Pharma AB (publ) since January 8, 2020. Mr. Jönsson served in a senior position at Ferring Pharmaceuticals in the US, he was business area dire...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.3yrs | kr2.41m | 0.66% SEK 773.9k | |
| Chief Financial Officer | 7.3yrs | no data | 0.20% SEK 231.5k | |
| Chief Scientific Officer | 4.3yrs | kr1.28m | 1.41% SEK 1.7m | |
| Chief Medical Officer & Head of Development | 3.1yrs | no data | 0.12% SEK 140.2k | |
| Head of Research & Discovery | 7.3yrs | no data | 1.46% SEK 1.7m |
4.3yrs
Average Tenure
56yo
Average Age
Experienced Management: ALZCUR's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.3yrs | kr200.00 | 2.42% SEK 2.8m | |
| Independent Director | 7.3yrs | kr115.00k | 0.080% SEK 93.9k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 6.3yrs | kr115.00k | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | less than a year | kr73.00k | 0.040% SEK 47.3k | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 3yrs | kr115.00k | 0.0040% SEK 4.7k |
6.3yrs
Average Tenure
67yo
Average Age
Experienced Board: ALZCUR's board of directors are considered experienced (6.3 years average tenure).